254In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013
نویسندگان
چکیده
254. In Vitro Activity of Ceftazidime in Combination with Avibactam vs 1825 Pseudomonas aeruginosa Clinical Isolates Obtained from across Canada as Part of the CANWARD Study, 2009-2013 Andrew Walkty, MD; Melanie Decorby, MSc; Heather J. Adam, PhD; Philippe Lagacé-Wiens, MD; James Karlowsky, PhD; Daryl Hoban, PhD; George Zhanel, PhD; Microbiology, Diagnostic Services of Manitoba, Health Sciences Centre, Winnipeg, MB, Canada; Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada; Department of Clinical Microbiology, Health Sciences Centre, Winnipeg, MB, Canada; Microbiology, Diagnostic Services of Manitoba, St. Boniface Hospital, Winnipeg, MB, Canada
منابع مشابه
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012.
The in vitro activity of ceftolozane in combination with tazobactam (fixed concentration of 4 μg/ml) was evaluated against 2,435 Pseudomonas aeruginosa clinical isolates obtained from across Canada using Clinical and Laboratory Standards Institute broth microdilution methods. The MIC50 and MIC90 values for ceftolozane-tazobactam were 0.5 μg/ml and 1 μg/ml, respectively (a 32-fold-lower MIC90 th...
متن کاملIn Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial Non-Susceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016
1217. In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial NonSusceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 Andrew Walkty, MD; Heather J. Adam, PhD; Melanie Baxter, MSc; Philippe Lagace-Wiens, MD; James Karlowsky, PhD; Daryl Hoban, PhD and George Zhanel, PhD; Diagnostic Services Manitoba, Winnipeg, MB, Canada, M...
متن کاملIn vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study).
The in vitro activity of ceftazidime in combination with NXL104 versus 470 Pseudomonas aeruginosa clinical isolates was evaluated using Clinical and Laboratory Standards Institute (CLSI) broth microdilution methods. Ceftazidime had MIC₉₀s of 8 μg/ml and 32 μg/ml in the presence and absence of NXL104, respectively. Of 25 multidrug-resistant P. aeruginosa isolates, the percentages with a ceftazid...
متن کاملIn vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates.
The β-lactamase inhibitor avibactam (NXL104) displays potent inhibition of both class A and C enzymes. The in vitro antibacterial activity of the combination ceftazidime-avibactam was evaluated against a clinical panel of Pseudomonas aeruginosa isolates. Avibactam offered efficient protection from hydrolysis since 94% of isolates were susceptible to ceftazidime when combined with 4 μg/ml avibac...
متن کاملIn Vitro Activity of Lefamulin against S. aureus Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia
1217. In Vitro Activity of Ceftolozane-Tazobactam vs. Antimicrobial NonSusceptible Pseudomonas aeruginosa Clinical Isolates Obtained from Across Canada as Part of the CANWARD Study, 2008–2016 Andrew Walkty, MD; Heather J. Adam, PhD; Melanie Baxter, MSc; Philippe Lagace-Wiens, MD; James Karlowsky, PhD; Daryl Hoban, PhD and George Zhanel, PhD; Diagnostic Services Manitoba, Winnipeg, MB, Canada, M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 1 شماره
صفحات -
تاریخ انتشار 2014